AcelRx Pharmaceuticals Stock News

REDWOOD CITY, Calif., Dec. 9, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therap

REDWOOD CITY, Calif., Dec. 4, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therap

Acelrx shares plummeted after the company released third quarter earnings. However, numbers were significantly up compared to any prior period.

REDWOOD CITY, Calif., Nov. 6, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therap

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q3 2020 Results - Earnings Call Transcript

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 42.86% and -25.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti

Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...

Stocks Analysis by Zacks Investment Research covering: Apple Inc, Ocular Therapeutix Inc, Tilray Inc. Read Zacks Investment Research's latest article on Investing.com

Zacks Investment Research lowered shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a buy rating to a hold rating in a research note published on Friday, Zacks.com reports. According to Zacks, “Ac

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 10, 2020. Ac